“The #1 Tech Opportunity of the Decade”

On February 8th, Luke Lango is making his biggest call of 2023. He’s recommending technology (that you’ve likely never heard of) that could help 122 million people… And mint up to $3 trillion in wealth.

Wed, February 8 at 8:00PM ET
 
 
 
 

Cathie Wood Keeps Buying Ginkgo Bioworks (DNA) Stock

  • Cathie Wood has been adding shares of biotech company Ginkgo Bioworks (DNA) to her exchange-traded funds (ETFs) in recent days.
  • The buys are bringing attention to Ginkgo, which specializes in genetic engineering.
  • However, Wood is still a controversial figure in investing, attracting both supporters and critics.
Person holding mobile phone with logo of American biotechnology company Ginkgo Bioworks Inc. on screen in front of web page. Focus on phone display. Unmodified photo. DNA stock
Source: T. Schneider / Shutterstock.com

Cathie Wood can’t seem to get enough of Ginkgo Bioworks (NYSE:DNA). Running ARK Invest, Wood has acquired more than 250,000 shares of DNA stock. The Boston-based biotechnology company finished trading at $3.31 per share on Oct. 5.

Wood has been buying DNA stock through her various exchange-traded funds (ETFs) which focus on companies engaged in disruptive technologies. Year-to-date (YTD), Wood’s flagship ARK Innovation ETF (NYSEARCA:ARKK) is down 58% and trading near $40 per share.

Here’s what investors should know about Ginkgo and Wood’s share purchases moving forward.

What’s Happening With DNA Stock?

Wood’s interest in Ginkgo Bioworks comes after the company made a series of strategic acquisitions. On Oct. 4, Ginkgo announced that it was acquiring biotech company Circularis to help bolster its cell and gene-therapy capabilities. At the same time, Ginkgo also acquired Altar, a French biotech name that has developed a “proprietary adaptive evolution platform.” Financial terms for either of these deals were not disclosed.

Founded in 2009 by several scientists at the Massachusetts Institute of Technology (MIT), Ginkgo is engaged in genetic engineering that produces bacteria which can be used in industrial applications. The company has been valued at as much as $4.2 billion. However, DNA stock has declined 61% this year and fallen 69% since its market debut in 2021 via a reverse merger with a special purpose acquisition company (SPAC).

Why It Matters

Cathie Wood’s stock picks are carefully scrutinized on Wall Street. Her flagship ARK Innovation fund has imploded this year after running up more than 300% between March 2020 and February 2021. In recent months, Wood has also been criticized for continuing to hold onto — and in some cases double down on — stocks that have collapsed this year. These include names like Roblox (NYSE:RBLX) and Spotify (NYSE:SPOT).

Wood has responded to the criticism by saying that innovation is on sale as markets trend lower. However, it’s interesting that she is buying shares of DNA stock. Typically, Wood focuses on larger tech companies with more established products in the marketplace. One of her largest holdings is electric vehicle (EV) maker Tesla (NASDAQ:TSLA), another stock she has continued to buy in 2022. Cathie Wood’s interest in Ginkgo is bringing the company and DNA stock some valuable attention.

It’s not clear how much of an impact Wood’s purchase of DNA stock is having on the share price. Shares have climbed slightly over the past five trading sessions, but that could be due to the company’s recent acquisitions. For the year, DNA stock is still down more than 60%. Investors should proceed with caution.

On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.

Read More:Penny Stocks — How to Profit Without Getting Scammed

On the date of publication, Joel Baglole did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

Joel Baglole has been a business journalist for 20 years. He spent five years as a staff reporter at The Wall Street Journal, and has also written for The Washington Post and Toronto Star newspapers, as well as financial websites such as The Motley Fool and Investopedia.


Article printed from InvestorPlace Media, https://investorplace.com/2022/10/cathie-wood-keeps-buying-ginkgo-bioworks-dna-stock/.

©2023 InvestorPlace Media, LLC